M
Makoto Ohno
Researcher at Toray Industries
Publications - 73
Citations - 1647
Makoto Ohno is an academic researcher from Toray Industries. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 53 publications receiving 1280 citations.
Papers
More filters
Journal ArticleDOI
Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss
Hideyuki Arita,Yoshitaka Narita,Shintaro Fukushima,Kensuke Tateishi,Yuko Matsushita,Akihiko Yoshida,Yasuji Miyakita,Makoto Ohno,V. Peter Collins,Nobutaka Kawahara,Soichiro Shibui,Koichi Ichimura +11 more
TL;DR: The data indicate that mutation of the TERT promoter is one of the major mechanisms of telomerase activation in gliomas, and suggests that they play distinct roles in the pathogenesis of oligodendroglial and astrocytic tumors.
Journal ArticleDOI
STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors.
Akihiko Yoshida,Koji Tsuta,Makoto Ohno,Masayuki Yoshida,Yoshitaka Narita,Akira Kawai,Hisao Asamura,Ryoji Kushima +7 more
TL;DR: Nuclear STAT6 immunoreactivity is a highly sensitive and specific marker of SFTs and can be helpful when diagnosis is inconclusive by conventional methods.
Journal ArticleDOI
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
Hideyuki Arita,Hideyuki Arita,Kai Yamasaki,Yuko Matsushita,Taishi Nakamura,Taishi Nakamura,Asanao Shimokawa,Hirokazu Takami,Hirokazu Takami,Shota Tanaka,Akitake Mukasa,Mitsuaki Shirahata,Saki Shimizu,Kaori Suzuki,Kuniaki Saito,Keiichi Kobayashi,Fumi Higuchi,Takeo Uzuka,Ryohei Otani,Kaoru Tamura,Kazutaka Sumita,Makoto Ohno,Yasuji Miyakita,Naoki Kagawa,Naoya Hashimoto,Ryusuke Hatae,Koji Yoshimoto,Naoki Shinojima,Hideo Nakamura,Yonehiro Kanemura,Yoshiko Okita,Manabu Kinoshita,Kenichi Ishibashi,Tomoko Shofuda,Yoshinori Kodama,Kanji Mori,Yusuke Tomogane,Junya Fukai,Koji Fujita,Yuzo Terakawa,Naohiro Tsuyuguchi,Shusuke Moriuchi,Masahiro Nonaka,Hiroyoshi Suzuki,Makoto Shibuya,Taketoshi Maehara,Nobuhito Saito,Motoo Nagane,Nobutaka Kawahara,Keisuke Ueki,Toshiki Yoshimine,Etsuo Miyaoka,Ryo Nishikawa,Takashi Komori,Yoshitaka Narita,Koichi Ichimura +55 more
TL;DR: The findings suggest that a combination of IDH, TERT, and MGMT refines the classification of grade II-IV diffuse gliomas, and patients with TERT mutant-MGMT unmethylated GBM have the poorest prognosis.
Journal ArticleDOI
Revisiting TP53 Mutations and Immunohistochemistry--A Comparative Study in 157 Diffuse Gliomas.
Hirokazu Takami,Akihiko Yoshida,Shintaro Fukushima,Hideyuki Arita,Yuko Matsushita,Taishi Nakamura,Taishi Nakamura,Makoto Ohno,Yasuji Miyakita,Soichiro Shibui,Yoshitaka Narita,Koichi Ichimura +11 more
TL;DR: In this paper, the authors re-evaluate the efficacy of p53 immunohistochemistry to predict the mutational status of TP53 and propose a moderately sensitive and highly specific marker to predict TP53 mutation.
Journal ArticleDOI
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
Yoshiko Okita,Yoshitaka Narita,Yasuji Miyakita,Makoto Ohno,Yuko Matsushita,Shintaro Fukushima,Minako Sumi,Koichi Ichimura,Takamasa Kayama,Soichiro Shibui +9 more
TL;DR: Among the patients with IDH1/2 mutations, those who were initially treated with chemoradiotherapy including nimustine hydrochloride (ACNU), had significantly longer PFS than those treated with radiotherapy alone, whereas no significant difference in PFS was observed between the cheMoradiotherapy and radiotherapy groups in the patients without IDH2 mutations.